---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-005104"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T01:57:55.329758+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences prelim Q4 2024 rev $18.9-19.1M (+1% YoY); Surgical Glaucoma +9%

## Summary
- Surgical Glaucoma revenue $18.7-18.8M (+9% YoY at midpoint); Dry Eye rev $0.2-0.3M vs $1.6M prior year.
- Full year 2024 total revenue $79.7-79.9M (-2% YoY); cash and equivalents ~$120M; $1.4M generated in Q4.
- New LCDs by five Medicare contractors effective mid-November restricted MIGS coverage, impacting results.
- Company plans to achieve cash flow breakeven without additional equity capital; FY 2024 cash used $18.1M down from $46.9M.

## SEC filing metadata
- accession: 0000950170-25-005104
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000095017025005104/0000950170-25-005104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000095017025005104/sght-20250114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-005104
- JSON: https://secwatch.observer/filing/0000950170-25-005104.json
- Plain text: https://secwatch.observer/filing/0000950170-25-005104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.